17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts Academic Article uri icon

Overview

MeSH Major

  • Prostatic Neoplasms
  • Receptor, ErbB-2
  • Receptors, Androgen
  • Rifabutin

abstract

  • These data demonstrate that, at a tolerable dose, inhibition of Hsp90 function by 17-AAG results in a marked reduction in HER2, AR, and Akt expression and inhibition of prostate tumor growth in mice. These results suggest that this drug may represent a new strategy for the treatment of prostate cancer.

publication date

  • May 27, 2002

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 12006510

Additional Document Info

start page

  • 986

end page

  • 93

volume

  • 8

number

  • 5